Medical Research

Cancer Research Institute, Inc.

The Leader in Immunotherapy

aka CRI

New York, NY


SAVE MORE LIVES by fueling the discovery and development of powerful immunotherapies for all types of cancer.

Ruling Year


CEO and Director of Scientific Affairs

Dr. Jill O'Donnell-Tormey Ph.D.

Main Address

29 Broadway, Floor 4

New York, NY 10006 USA


cancer, immunology, research, antibodies, vaccines, CAR T, immunotherapy





Cause Area (NTEE Code)

Cancer Research (H30)

Fund Raising and/or Fund Distribution (H12)

IRS Filing Requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2017, 2017 and 2016.
Register now

Social Media


Programs + Results

What we aim to solve New!

Decades of scientific research have confirmed that our own immune systems are able to see and eliminate cancer. Recent clinical trials have also demonstrated that immunotherapy--treatments that mobilize the immune system to fight cancer--can be an effective treatment for some patients. More scientific research is needed, however, to learn why some patients respond to treatment while others do not. More clinical trials are needed to test immunotherapy in more types of cancer as well as to find optimal combinations that have the greatest potential of benefiting patients. CRI is committed to driving the science of cancer immunology forward so that we will one day soon see a future immune to cancer.

Our programs

What are the organization's current programs, how do they measure success, and who do the programs serve?

SOURCE: Self-reported by organization

CRI Irvington Postdoctoral Fellowship Program

Clinic and Laboratory Integration Program (CLIP)

Clinical Accelerator

Grants and Patient Support

Annual Honorary Awards

Where we workNew!

Our Results

How does this organization measure their results? It's a hard question but an important one. These quantitative program results are self-reported by the organization, illustrating their committment to transparency, learning, and interest in helping the whole sector learn and grow.

SOURCE: Self-reported by organization

Total number of grants awarded

Population(s) served

No target populations selected

Context notes

Includes CRI Irvington Postdoctoral Fellowships, Clinic and Laboratory Integration Program grants, Clinical Accelerator trial grants, designated Impact Grants, and annual awards.

Total dollar amount of grants awarded

Population(s) served

No target populations selected

Context notes

Includes CRI Irvington Postdoctoral Fellowships, Clinic and Laboratory Integration Program grants, Clinical Accelerator trial grants, designated Impact Grants, and annual awards.

Charting Impact

Five powerful questions that require reflection about what really matters - results.

SOURCE: Self-reported by organization

What is the organization aiming to accomplish?

What are the organization's key strategies for making this happen?

What are the organization's capabilities for doing this?

How will they know if they are making progress?

What have and haven't they accomplished so far?

Over the next five years, the Cancer Research Institute will aim to:
(a) bring increasingly effective cancer immunotherapies to more cancer patient populations;
(b) expand awareness among patients, caregivers, and health care professionals of the power of cancer immunotherapy and its significant potential to slow or halt tumor growth, delay or prevent cancer recurrence, and extend patient lives;
(c) grow the general public's awareness of the revolution in cancer treatment and the need to continue funding critical research in order to optimize immunotherapy for more groups of cancer patients;

CRI will achieve its goals through: (a) expanding the field's knowledge by funding laboratory research in immunology and tumor immunology at universities and medical centers around the globe; (b) channeling new incremental funds into our translational and clinical research programs, which aim to test and optimize cancer immunotherapies; (c) forging new collaborations with more pharmaceutical and biotech industry partners as well as nonprofit partners in order to gain access to highly promising immunotherapies and test them in our international clinical trials network; (d) launching a new campaign targeting cancer patients and caregivers designed to educate these groups on cancer immunotherapy, connect them with one another to exchange experiences and knowledge, and motivate them to ask their oncologists about immunotherapy options when appropriate;

The Cancer Research Institute is uniquely positioned to carry out the strategies above. (a) Our longstanding postdoctoral fellowship program ensures a steady stream of intellectual talent to drive the field’s progress. Fellows ask fundamental questions about the immune system and its relationship to cancer, gaining new knowledge that fuels translational and clinical application. (b) Through our Clinic and Laboratory Integration and Clinical Accelerator programs, we accelerate clinically-relevant discovery and optimization of immunotherapy in a wide variety of cancer types. (d) As cancer immunotherapy enters the mainstream of treatment for more types of cancer, the need for trusted information about the available treatment options, how they work, and their potential side effects grows. Our website and offline events for patients and caregivers helps educate the public about this new approach to cancer treatment.

For our clinical program, progress is measured via milestones in the clinical trial development process. Another important milestone is when promising therapeutic strategies developed in our early stage clinical incubator are taken to larger phase three trials and, if successful, receive regulatory approval for patient treatment. Our clinic-laboratory program is successful if it identifies new ways to improve cancer immunotherapy in humans, increasing their effectiveness and expanding their applicability to multiple cancer types. We continue also to monitor the career trajectories of students and postdoctoral fellows who receive funding from the Cancer Research Institute. Many go on to become leaders in the field by receiving the best expert mentoring, discovering seminal knowledge through their laboratory research, and contributing to the development of new treatment strategies.

In the 65 years since CRI's founding, our scientists have made significant progress in advancing our understanding of the immune system and its response to cancer. This knowledge has resulted in game-changing treatments that harness the immune system's power to conquer cancer and save lives. CRI scientists have laid a solid foundation of insights that have spurred the technological advances that make possible today's medical advances in cancer immunotherapy. The face of cancer treatment is changing, and the disease will soon become one that is manageable and in some cases curable rather than deadly. As we look to the decade ahead, the Cancer Research Institute will continue to lead the field through its ability to establish unique, philanthropy-based partnerships between nonprofit and for-profit entities engaged in cancer immunotherapy research and development.

External Reviews

Awards & Accreditations

Better Business Bureau Wise Giving Alliance

Charity Navigator



Cancer Research Institute, Inc.

Fiscal year: Jul 01 - Jun 30

Need more info on this nonprofit?

Need more info on this nonprofit?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2017, 2017 and 2016
A Pro report is also available for this organization for $125.
Click here to view a Sample Report.


The people, governance practices, and partners that make the organization tick.

Need more info?

FREE: Gain immediate access to the following:

  • Address, phone, website and contact information
  • Forms 990 for 2017, 2017 and 2016
A Pro report is also available for this organization for $125.
Click here to see what's included.

Board Leadership Practices

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section, which enables organizations and donors to transparently share information about essential board leadership practices.

SOURCE: Self-reported by organization


Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations?



Has the board conducted a formal, written assessment of the chief executive within the past year?



Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year?



Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership?

Not Applicable


Has the board conducted a formal, written self-assessment of its performance within the past three years?


Organizational Demographics

In order to support nonprofits and gain valuable insight for the sector, GuideStar worked with D5—a five-year initiative to advance diversity, equity, and inclusion in philanthropy—in creating a questionnaire. This section is a voluntary questionnaire that empowers organizations to share information on the demographics of who works in and leads organizations. To protect the identity of individuals, we do not display sexual orientation or disability information for organizations with fewer than 15 staff. Any values displayed in this section are percentages of the total number of individuals in each category (e.g. 20% of all Board members for X organization are female).

SOURCE: Self-reported by organization


Race & Ethnicity

This organization reports that it does not collect this information for Board Members and Part-Time Staff.

Sexual Orientation

Diversity Strategies

We track retention of staff, board, and volunteers across demographic categories
We track income levels of staff, senior staff, and board across demographic categories
We track the age of staff, senior staff, and board
We track the diversity of vendors (e.g., consultants, professional service firms)
We have a diversity committee in place
We have a diversity manager in place
We have a diversity plan
We use other methods to support diversity